guest ::
| Home > Publications database > T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis. > print |
| Home > Publications database > T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis. > print |
| 001 | 178512 | ||
| 005 | 20251118115242.0 | ||
| 024 | 7 | _ | |a 10.1002/hep.32336 |2 doi |
| 024 | 7 | _ | |a pmid:35023202 |2 pmid |
| 024 | 7 | _ | |a 0270-9139 |2 ISSN |
| 024 | 7 | _ | |a 1527-3350 |2 ISSN |
| 024 | 7 | _ | |a altmetric:120898276 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00109 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ramadori, Pierluigi |0 P:(DE-He78)6e985c345eb4618b127cf0fe1bff1522 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis. |
| 260 | _ | _ | |a New York [u.a.] |c 2022 |b Wiley Interscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1763463150_1939190 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F180#LA:F180# / 2022 Apr;75(4):1038-1049 / #DKFZ-MOST-Ca197# |
| 520 | _ | _ | |a In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD-related HCC is increasing almost exponentially. In recent years, many of the underlining multi-factorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to single-cell level. However, there is still an urgent need to provide clinicians with more therapeutic targets, with particular attention on NAFLD-induced HCC, where immune check-point inhibitors do not work as efficiently. Whereas much effort has been invested in elucidating the role of the innate immune response in the hepatic NAFLD microenvironment, only in the last decade novel critical roles were unraveled for T cells in driving chronic inflammation toward HCC. The metabolic and immune-microenvironment interact to recreate a tumor-promoting and immune-suppressive terrain, responsible for the resistance to anti-cancer therapy. In this article, we will review the specific functions of several T-cell populations involved in NAFLD and NAFLD-driven HCC. We will illustrate the cellular cross talk with other immune cells, the regulatory networks or stimulatory effects of these interactions and the role of the metabolic microenvironment in influencing immune-cell functionality. Finally, we will present the pros and cons of the current therapeutic strategies against NAFLD-related HCC and delineate possible novel approaches for the future. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 700 | 1 | _ | |a Kam, Shing |0 P:(DE-He78)6560c1a687d2ad37d0240771fefecf16 |b 1 |u dkfz |
| 700 | 1 | _ | |a Heikenwälder, Mathias |0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |b 2 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1002/hep.32336 |g p. hep.32336 |0 PERI:(DE-600)1472120-X |n 4 |p 1038-1049 |t Hepatology |v 75 |y 2022 |x 0270-9139 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:178512 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)6e985c345eb4618b127cf0fe1bff1522 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)6560c1a687d2ad37d0240771fefecf16 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-19 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HEPATOLOGY : 2021 |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-19 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b HEPATOLOGY : 2021 |d 2022-11-19 |
| 920 | 2 | _ | |0 I:(DE-He78)F180-20160331 |k F180 |l Chronische Entzündung und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F180-20160331 |k F180 |l Chronische Entzündung und Krebs |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)F180-20160331 |k F180 |l Chronische Entzündung und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F180-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|